ReviewBiochimica et biophysica acta. Molecular and cell biology of lipids2017
Bacterial fatty acid metabolism in modern antibiotic discovery.
Review in Biochimica et biophysica acta. Molecular and cell biology of lipids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 105 citations in OpenAlex.
- Trial
- Integrated Transcriptomics and Metabolomic Profiling Suggests That Thymol Adaptation Induces Multi-Layered Envelope and Metabolic Perturbations That SensitizeInternational journal of molecular sciences · 2026Article
- Questiomycin A demonstrates antibacterial activity against Mycobacterium tuberculosis by directly targeting FabD.Communications biology · 2026Article
- Disinfectant-induced bacterial resistance and antibiotic cross-resistance-mechanisms and clinical relevance.Clinical and experimental medicine · 2025Review
- Global health perspectives on antibacterial drug discovery and the preclinical pipeline.Nature reviews. Microbiology · 2025Review
- Not too rigid nor too wobbly: Defining an optimal membrane fluidity range essential for biofilm formation inmLife · 2025Article
- Combating Antimicrobial Resistance: Innovative Strategies Using Peptides, Nanotechnology, Phages,Pharmaceuticals (Basel, Switzerland) · 2025Review
- Functional disparities of malonyl-ACP decarboxylase betweenApplied and environmental microbiology · 2025Article
- Current Trends in Antibiotic Therapy and Resistance: A Comparative Study of Various Spectrums.Cureus · 2025Article
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- SCO6564, a novel 3-ketoacyl acyl carrier protein synthase III, contributes in fatty acid synthesis in Streptomyces coelicolor.PloS one · 2025Article
- Total Synthesis of the Phenylnaphthacenoid Type II Polyketide Antibiotic Formicamycin H via Regioselective Ruthenium-Catalyzed Hydrogen Auto-Transfer [4 + 2] Cycloaddition.Journal of the American Chemical Society · 2024Article
- Optimizing Archaeal Lipid Biosynthesis inACS synthetic biology · 2024Article
- Isocyanides inhibit bacterial pathogens by covalent targeting of essential metabolic enzymes.Chemical science · 2024Article
- Integrated Metabolomic and Transcriptomic Analysis Reveals the Underlying Antibacterial Mechanisms of the Phytonutrient Quercetin-Induced Fatty Acids Alteration inMolecules (Basel, Switzerland) · 2024Article
- Evaluation ofACS infectious diseases · 2024Article
- Design, quality and validation of the EU-OPENSCREEN fragment library poised to a high-throughput screening collection.RSC medicinal chemistry · 2024Article
- Structural and functional characterization of FabG4 from Mycolicibacterium smegmatis.Acta crystallographica. Section F, Structural biology communications · 2024Article
- Article
- Structure features ofFrontiers in molecular biosciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bacterial fatty acid synthesis is essential for many pathogens and different from the mammalian counterpart. These features make bacterial fatty acid synthesis a desirable target for antibiotic discovery. The structural divergence of the conserved enzymes and the presence of different isozymes catalyzing the same reactions in the pathway make bacterial fatty acid synthesis a narrow spectrum target rather than the traditional broad spectrum target. Furthermore, bacterial fatty acid synthesis inhibitors are single-targeting, rather than multi-targeting like traditional monotherapeutic, broad-spectrum antibiotics. The single-targeting nature of bacterial fatty acid synthesis inhibitors makes overcoming fast-developing, target-based resistance a necessary consideration for antibiotic development. Target-based resistance can be overcome through multi-targeting inhibitors, a cocktail of single-targeting inhibitors, or by making the single targeting inhibitor sufficiently high affinity through a pathogen selective approach such that target-based mutants are still susceptible to therapeutic concentrations of drug. Many of the pathogens requiring new antibiotic treatment options encode for essential bacterial fatty acid synthesis enzymes. This review will evaluate the most promising targets in bacterial fatty acid metabolism for antibiotic therapeutics development and review the potential and challenges in advancing each of these targets to the clinic and circumventing target-based resistance. This article is part of a Special Issue entitled: Bacterial Lipids edited by Russell E. Bishop.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.